Teva Pharmaceutical Industries. Information about the issuer. (LEI 549300BAFGM4RC74ZJ94, SWIFT TEVPILITXXX). News and credit ratings. Tables with accounting and financial reports.
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
Laquinimod - Wikipedia
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
Teva Relinquishes Laquinimod, Returning the Rights to Active Biotech - Pharmaceutical Processing World
Teva Pharmaceuticals - Wikipedia
Production at Teva API plant halted until next year | Fierce Pharma
Teva posts positive phase 3 migraine data, plots FDA submission | Fierce Biotech
Active Biotech's partner Teva starts laquinimod clinical trial
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
CHMP says no to Laquinimod
Weekly Biotech Report covering Vantrela by Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) - Market Exclusive
Active Biotech and Teva remain committed to clinical development program for multiple sclerosis
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
Teva Pharmaceutical Industries - Crunchbase Company Profile & Funding
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Active Biotech regains rights of laquinimod from Teva
Fortified with sentiment and cash, Active Biotech presses on | Evaluate
Active Biotech Regains Rights to Laquinimod from Teva, Plans to Continue Work on Potential MS Oral Therapy
NORMAL.DOT för Office 97
